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Abstract
Rheumatoid arthritis (RA) is a chronic and disabling polyarthritic disease, which affects mainly women in middle and old age.
Extensive evidence based on the results of various microbial, immunological and molecular studies from different parts of
the world, shows that a strong link exists between Proteus mirabilis microbes and RA. We propose that sub-clinical Proteus
urinary tract infections are the main triggering factors and that the presence of molecular mimicry and cross-reactivity
between these bacteria and RA-targeted tissue antigens assists in the perpetuation of the disease process through production of
cytopathic auto-antibodies.
Patients with RA especially during the early stages of the disease could beneﬁt from Proteus anti-bacterial measures involving
the use of antibiotics, vegetarian diets and high intake of water and fruit juices such as cranberry juice in addition to the
currently employed treatments.
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Introduction
Rheumatoid arthritis (RA) is a chronic inﬂammatory
joint disease, which affects millions of people all
around the world, with a prevalence rate ranging from
0.5 to 1% (Lawrence et al. 1998). The disease in the
majority of patients takes a mild to moderate course,
whilst in others it has a more disabling consequence,
which might have a great effect on the socio-economic
status of the patient (Cooper 2000).
RA affects individuals of middle age groups and
occurs three times more frequently in women than
in men.
Aetiopathogenesis
A general scientiﬁc consensus exists, which considers
RA as an immune-mediated disease that could
possibly be triggered by an environmental (microbial)
factor in a genetically susceptible individual.
Extensive evidence supports the role of cellular and
humoral autoimmunity in the development of RA, and
some of these are listed as follows:
1. Predominant role of B lymphocytes in the
pathogenesis of RA (Weyand et al. 2005) and
signs of accumulations of immunoglobulins and
other inﬂammatory products such as complements
at the site of synovial pathological lesions in RA
patients (Low and Moore 2005).
2. Detection of elevated levels of auto-antibodies in
the serum and/or synovial ﬂuid of patients with RA
(Rantapaa-Dahlqvist 2005).
3. Signiﬁcant improvements in RA disease para-
meters following B cell depletion therapy, e.g. with
the use of anti-CD20 antibodies (Perosa et al.
2005).
Role of HLA genes in RA
The role of genetics in development of RA has been
examined mainly through family, twin and molecular
analytical studies. For instance, familial distribution of
RA among ﬁrst-degree relatives (Deighton et al.
1992a) and twins (MacGregor et al. 2000), indicates
that RA runs in some families, basically supporting the
ISSN 1740-2522 print/ISSN 1740-2530 online q 2006 Taylor & Francis
DOI: 10.1080/17402520600576578
Correspondence: A. Ebringer, Infection and Immunity Group, School of Biomedical and Health Science, King’s College London, 150
Stamford Street, London SE1 9NN, UK. Tel: 44 20 7848 4302. Fax: 44 20 7848 4500. E-mail: alan.ebringer@kcl.ac.uk
Clinical & Developmental Immunology, March 2006; 13(1): 41–48concept of a genetic contribution, but at the same time
arguing against the proposition that RA could be
considered as a purely genetic disorder. However, in
two separate genome-wide screenings with affected sib
pairs, it has been shown that HLA haplotypes had the
largest genetic contribution in RA (Cornelis et al.
1998; Jawaheer et al. 2001).
Nearly three decades ago, HLA-DR4 was the ﬁrst
genetic marker among other class II molecules, found
to be signiﬁcantly liked with RA susceptibility (Stastny
1976). It has been shown later that various other
HLA-DRB1 alleles were either associated (HLA-
DRB*0101, *0102, *0401, *0404, *0405, *1001 and
1402) or not associated (HLA-DRB*0103, *0402,
*0403 and *0408) with RA (Newton et al. 2004),
based on certain differences occurring within amino
acid sequences at the location 69–74 “EQRRAA”
which has been termed as the “shared epitope” (SE)
moiety (Gregersen et al. 1987).
Regardless of the difference in the distribution of
HLA genes among various ethnic groups, it has been
reported that more than 95% of patients possess at
least one of the RA-linked HLA-DR molecules
(Weyand et al. 1992), which contain the “SE” amino
acid sequence. Further to its role in conferring the
disease susceptibility, these RA-associated HLA-
DRB1 alleles have also been reported to have a great
impact on the disease severity and extra-articular
manifestations in patients with RA (Turesson et al.
2005).
Immunological and molecular links between RA and
Proteus
During the last 3 decades an extensiveliterature on the
link between Proteus microbes and RA has been
published in peer-reviewed journals. These studies
were carried out by various independent groups
worldwide. Some of this evidence, listed in chrono-
logical orders, can be summarized as follows: (Table I)
1. In early 1970s, a group from Tennessee reported
an increase in the geometric mean titres of
antibodies to Proteus OXK and herpes virus
hominis but not to 28 other infectious disease
antigens in RA patients when compared to
controls (Chandler et al. 1971).
2. In mid 1980s, our group reported for the ﬁrst
time that antibody levels against P. mirabilis,a
urinary pathogen, were signiﬁcantly elevated in
RA patients when compared to those with
ankylosing spondylitis (AS) or healthy control
subjects (Ebringer et al. 1985).
3. In early 1990s, we have identiﬁed an amino acid
sequence homology between the “EQ/KRRAA”
aminoacidmotifpresentinRAHLA-susceptibility
moleculesandthe“ESRRAL”sequencepresentin
P . mirabilis haemolysins (Ebringer et al. 1992).
4. In mid 1990s, our group has found another
molecular homology between “LRREI” amino
acid sequence present in type XI collagen and
“IRRET” amino acid motif present in Proteus
urease enzymes (Wilson et al. 1995).
5. In late 1990s, in vitro and in vivo immunological
cross reactivities have been observed between
synthetic peptides from Proteus haemolysin and
urease enzyme molecules and those of HLA-
DR1/DR4andcollagenself-antigens(Tiwanaetal.
1999). Furthermore, Senior and colleagues from
Dundee, have found that Proteus mirabilis is the
most prominent microbe encountered in the urine
of RA patients, who had bacteriuria more
frequently than age- and sex-matched healthy
controls (Senior et al. 1999).
6. In the year 2003, our group has shown that anti-
ESRRAL Proteus antibodies from patients with
active RA can haemolyse sheep red blood cells
(SRBC) coated with HLA-DR4/1-containing
“EQRRAA” but not HLA-B27-containing
“QTDRED” amino acid synthetic peptides more
frequently than patients with AS and healthy
controls. By contrast, active AS patients with high
anti-QTDRED Klebsiella antibodies had higher
levels of an invitro haemolytic reactions on SRBCs
coated with “QTDRED” but not “ESRRAL”
syntheticpeptideswhen compared topatientswith
RA or to healthy controls (Wilson et al. 2003).
Hence,RAandASgroupsofpatientscouldbehave
as reciprocal controls to each other concerning the
involvement of antibodies against Proteus antigens
in RA and Klebsiella antigens in AS. Blood donors
did not react against either Proteus or Klebsiella
antigens.
7. Betweentheyear1985and2003,manyserological
studies have been carried out by various indepen-
dentgroups.Cumulatively,theyshowthatelevated
antibodies against various antigens from Proteus
mirabilis were observed in more than 1350 RA
patients from 15 different countries worldwide
when compared to corresponding healthy controls
(Ebringer et al. 2003).
8. In the year 2004, a collaborative study was carried
outinvolvingFinishandJapanesepatientswithRA.
Itwasobservedthatthesepatientswereallshowing
signiﬁcantly elevated levels of IgG antibodies to
whole and synthetic peptide antigen preparations
from P .mirabilisbutnottothosefromE.coliandS.
marcescensbacteriawhencomparedtocorrespond-
inghealthycontrolsorpatientswithsystemiclupus
erythematosus (Rashid et al. 2004).
9. In a recent multi-centre prospective study, it has
been shown that rheumatoid factor-(RF) positive
patients with RA had signiﬁcantly elevated levels
of IgM and IgA antibodies against Proteus
mirabilis and IgA antibodies against E. coli when
compared to disease and healthy control subjects
A. Ebringer & T. Rashid 42Table I. Chronologically listed evidence of microbiological, molecular and immunological links between Proteus microbes and rheumatoid
arthritis
Reference Basic results Methods used
Chandler et al. (1971) Elevated antibodies to Proteus OXK
and herpes virus but not to 22 other
microbial agents in RA patients
when compared HCs.
Direct agglutination assay
Ebringer et al. (1985) Elevated antibodies to P. mirabilis
but not Klebsiella microbes in
patients with RA when compared to
AS patients and HCs.
Indirect agglutination assay
Abuljadayel et al. (1988) Elevated anti-Proteus antibodies
in RA patients compared to HCs.
IIF
Rogers et al. (1988) Elevated levels of anti-Proteus antibodies
in RA patients compared to other
disease or healthy controls.
ELISA
Nasonova et al. (1989) Increased anti-Proteus antibodies in
the majority of Russian RA patients
when compared to corresponding
disease or healthy controls.
ELISA
Wilson et al. (1990) Increased isolation of P . mirabilis from
urine of RA patients when compared
to patients with OA or to HCs.
CLED (Oxoid Ltd) growth
and API20E (bioMerieux, Inc)
identiﬁcation methods
Deighton et al. (1992b) Absence of positive correlations
between elevated antibodies to P . mirabilis
and antibodies against 4 viruses and
8 auto-antigens in patients with RA
when compared to HCs
IIF
Ebringer et al. (1992) Molecular homology between Proteus
haemolysins and HLA-DR4/1 antigens.
SwissProt and GenBank
database search
Ebringer et al. (1993) Increased isolation rate of P. mirabilis
from urine of female more than male
patients with RA and in RA patients
as a whole when compared to healthy
subjects.
CLED growth and API20E
(bioMerieux, Inc)
identiﬁcation methods
Fielder et al. (1995) Elevated antibodies to P. mirabilis but
not to E. coli or S. Typhi bacteria in
French patients with RA
when compared to corresponding HCs.
ELISA and IIF
Subair et al. (1995) Elevated antibodies to P. mirabilis but not
to E. coli or other normal bowel microbial
inhabitants in Bermudian patients with
RA when compared to corresponding HCs.
ELISA and IIF
Wilson et al. (1995) Molecular similarities between Proteus
urease and collagen type XI antigens.
Elevated antibodies to Proteus haemolysin
and urease as well as
to HLA-DR4/1 and collagen antigenic peptides.
SwissProt and GenBank
database search and
ELISA
Tiwana et al. (1996) Elevated antibodies to Proteus but not to Serratia,
Escherichia and Pseudomonas bacteria in
RA patients when compared to HCs.
ELISA
Wanchu et al. (1997) Elevated antibodies to P. mirabilis but not
to S. typhi in Indian patients with RA when
compared to OA patients and to
HCs.
Tube agglutination
Wilson et al. (1997) A positive correlation between high serum
anti-Proteus antibody levels and urine Proteus
isolation rates in patients with RA.
ELISA and API20E methods
Blankenberg-Sprenkels et al. (1998) Elevated anti-Proteus but not anti-Klebsiella
antibodies in Dutch RA patients when
compared to patients with AS or to HCs.
IIF
Tiwana et al. (1999) In vitro and in vivo immunological
cross-reactivities between antibodies against
P. mirabilis and self-antigenic peptide molecules.
ELISA and peptide binding
dilution assay
Rashid et al. (1999) Elevated antibodies to P. mirabilis in Spanish
and Norwegian patients with RA when
compared to corresponding HCs.
IIF
Urinary tract infection triggers RA 43(Newkirk et al. 2005). However, many other
studies carried out previously had shown that only
anti-Proteus but no anti-E. coli antibodies were
observedtobeelevatedinRApatients(Fielderetal.
1995, Subair et al. 1995; Tiwana et al. 1996; Tani
et al. 1997; Rashid et al. 2004).
10. In another study carried out by a group from Los
Angeles, RA patients were reported to have IgA
anti-Proteus antibodies detectable more than in
healthy controls. However, several molecules from
this microbe had shown reduced IgA immune
responses compared to controls (Weisbart et al.
2005). It has been suggested that the occurrence
of some “holes” in the IgA immune repertoire for
certain antigens in Proteus bacteria could explain
the possibility that RA patients are more liable to
harbour this microbe and to have more frequent
bouts of (albeit, sub-clinical) infections, with a
consequent intermittent and/or progressive
enhancement of anti-Proteus antibody responses.
11. Most recently, our group has studied the humoral
immune responses against a new antigenic moiety
from Proteus urease F enzyme, which was found to
be non homologous to RA-targeted synovial tissue
structures. We have shown that active RA patients
hadsigniﬁcantlyelevatedIgGandIgManti-Proteus
peptide antibodies when compared to healthy
controls (Rashid et al. submitted). This latter
ﬁnding argues against the suggestion that elevated
antibodiesagainsttheProteuscrossreactiveantigens
in RA patients could be an epiphenomenona
resulting from increased exposure of auto-antigens
duetopathologicaldamagesproducedbybacterial
triggers.
Proteus urinary tract infections and RA
Various microbiological and immunological data
results support the suggestion that there is a link
between RA and urinary tract infections (UTI) mainly
caused by Proteus (Table II).
Patients with RA were reported to have a higher
frequency of recurrent UTIs (Lawson and Maclean
1966; Tishler et al. 1992). Urine samples from RA
patients yield higher isolation rates of P. mirabilis
microbes than patients with osteoarthritis or healthy
controls (Ebringer et al. 1993). RA patients had higher
levels of antibodies against Proteus in their urine when
compared to those of healthy subjects (Senior et al.
1999) and signiﬁcant correlation was detected
between serum anti-Proteus antibodies and Proteus
urinary isolation rates in RA patients when compared
to healthy controls (Wilson et al. 1997). Furthermore,
RA patients group who were receiving a vegetarian
diet had a drop in the levels of antibodies against
P. mirabilis but not E. coli, when compared to those
patients who were omnivores (Kjeldsen-Kragh et al.
1995). This dietary treatment may have exerted its
speciﬁc anti-microbial effect via the actions of lignans
and phytoestrogen metabolites (Adlercreutz et al.
Table I – continued
Reference Basic results Methods used
Senior et al. (1999) Sub clinical Proteus bacteriuria and
elevated levels of anti-Proteus antibodies
in urine and serum of patients with RA
when compared to HCs.
ELISA and Immunoblot
Ushakova et al. (2000) Elevated IgM and IgG antibodies to
P. mirabilis in Russian patients with RA
when compared to HCs.
ELISA
Wilson et al. (2003) In vitro immunological cytotoxicity
reaction occurring between anti-Proteus
and anti-HLA-DRB1 antibodies
with the corresponding
crossreactive peptide molecules.
ELISA and sheep red
cell haemolytic assays
Rashid et al. (2004) Finish and Japanese patients with RA
had elevated antibodies against whole
and synthetic peptide antigenic
preparations from P. mirabilis but not
those from E. coli and S. marcescens
when compared to corresponding HCs.
ELISA and IIF
Newkirk et al. (2005) Elevated IgM and IgA antibodies to
P. mirabilis and IgA antibodies to
E. coli but not to 6 other bacterial
and viral agents in rheumatoid factor
positive RA patients when compared to
those with other rheumatic diseases.
ELISA
ELISA ¼ Enzyme linked immunosorbent assay; HCs ¼ Healthy controls; IIF ¼ Indirect immunoﬂuorescence; RA ¼ Rheumatoid
arthritis; AS ¼ Ankylosing spondylitis; OA ¼ Osteoarthritis; CLED ¼ Cystine lactose-electrolyte deﬁcient.
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activity in vitro (Ito et al. 1982).
Females are more vulnerable to develop UTIs than
males and up to 60% of women have been reported to
develop at least one episode of UTI in their lifetime
(Foxman et al. 2000). A signiﬁcant number of these
women might have recurrent infections, and the
chance of infection by Proteus species was found to
increase with age (Nicolle 1996).
The increased incidence of UTIs in RA patients and
the more frequent occurrence of UTIs in females,
especially those of middle age and elderly groups
might give an answer to the higher prevalence of RA
among women.
Molecular mimicry as a plausible
aetiopathogenetic mechanism
Molecular and immunological inter-relation between
the triggering aetiological factor, namely Proteus
mirabilis antigens, and targeted synovial tissue struc-
tures expressing HLA molecules that contain “SE”
amino acid motif and collagen type XI, in RA could be
explained by the molecular mimicry or cross-reactivity
mechanism (Ebringer et al. 2005). High antibody
titres against Proteus haemolysin and urease antigens
in patients with active RA could bind to cross-reactive
self antigens and consequently result in production
of various inﬂammatory and immunological
damaging mediators based on the mechanism of
antibody-mediated cytotoxicity reactions (Figure 1).
Damage to the synovial and other joint structures
could result in the release of self-antigenic particles
and auto-antibody production. Anti-Proteus cross-
reactiveantibodies, which might result from recurrent,
albeit subclinical UTIs, together with high levels of
secondary auto-antibodies will bind to RA-targeted
antigens in the synovial tissues. These immunological
reactions could coincide with the initiation of clinical
and laboratory exacerbations and further pathological
damages.
Proposal of a new therapeutic strategy
Currently patients with RA are treated with various
therapeutic strategies involving the use of anti-
inﬂammatory, immunosuppressive and biological
agents as well as non-medical treatment modalities
(Genovese and Harris 2005).
Although, the current medical treatments,
especially those involving anti-tumour necrosis factor
therapies (Haraoui 2005), have a promising beneﬁcial
effect particularly in easing or even halting the disease
progress, they are expensive (Merkesdal et al. 2004)
and cause side-effects. In order, to achieve a
prolonged clinical remission, continuous immuno-
suppression with these drugs is required because this
kind of treatment could not eradicate the causative
microbial agents.
Based on the existing evidence for involving Proteus
bacteria in the pathogenesis of RA, it is logical to
propose a new therapeutic modality in the manage-
ment of RA, which could be implemented in
conjunction with other currently used treatments.
This new treatment includes anti-Proteus measures
involving the use of Proteus-sensitive antibiotics with
dietary manipulations in the forms of vegetarian diet
(Kjeldsen-Kragh et al. 1995) and high daily intake of
water and fruit juices containing fructose such as
cranberry juice (Rashid et al. 2001).
It could also be possible to make a vaccine mainly
derived from Proteus antigenic molecules that do not
contain the cross-reactive epitopes, in order to prevent
susceptible individuals of acquiring Proteus UTIs and
decrease the chance of developing RA or at least limit
further damages in those with established disease.
Conclusion
Based on the results of various studies carried out in
relation to Proteus microbes, it could be said that
compelling evidence exists linking this microbe to RA,
starting with recurrent sub-clinical Proteus UTIs and
ending in the full development of RA. To prove the
scientiﬁc logic of this possibility, and its beneﬁt to
patients clinical trials using anti-Proteus measures in
RA are required to be carried out in prospective
longitudinal studies.
Table II. Direct and indirect evidence of the links between Proteus
UTIs and RA
Direct evidence:
1) Proteus mirabilis bacteria were isolated more frequently in patients
with RA than those with other disease and healthy controls (Wilson
et al. 1990; Senior et al. 1999).
2) A positive correlation has been detected between anti-Proteus
antibodies and the rate of isolation of these microbes from urine of
RA patientswhen compared to healthysubjects (Wilsonet al.1997).
3) RA patients receiving vegetarian diet are more liable to have
decreased levels of anti-Proteus antibodies than omnivores
(Kjeldsen-Kragh et al. 1995).
4) Elevated levels of anti-Proteus antibodies were observed in sera of
RA patients coming from 15 different countries (Ebringer et al.
2003).
Indirect evidence:
1) Patients with severe RA had a higher frequency of recurrent UTIs
(Tishler et al. 1992).
2) Women are moreliableto developrecurrent UTIs(Franco2005).
This ﬁnding in combination to point number 1 above, could explain
why RA is more common among women than men.
3) Proteus bacteria, which are urease-positive, account for 15% of
UTIs, and affect the upper urinary tract, especially kidneys, whilst
E. coli, another urogenic but urease-negative bacteria, account for
the majority of UTIs and mainly involve bladder (Cattell 2005).
4) Patients with recurrent UTIs are more likely to respond to high
daily intake of cranberry juice (Raz et al. 2004). Whether cranberry
juice could have a beneﬁcial effect in patients with RA needs to be
investigated in a prospective controlled study.
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